	RSV and COVID-19	Enhanced Admission F		e Critical C	are – Aduli	
imeannacht na Seirbhíse Sláinte					6	hpsc /
lealth Service Executive		sive Care Societ				
Please complete this form f Idmissio <u>n to ICU. Please ex</u>		/Influenza/KSV	was the prima	ry or contribution	ng cause of	
orename	Surname		MRN			
ООВ:	Age:	ex: Female	Male Pa	tient Eircode		
Public Health Region of Resider	псе	County of Resid	ence	Country of Re	esidence	
Country of birth	Ethnic	ity	0	ccupation		
GP Name	Heal	th care worker Y	'es 📄 No	Unknowi	n 🗌	
GP Telephone	GP Ac	ldress				
All information co	ompleted on this form should	relate to the patie	ent's admission to	o THIS hospital, no	t referring hospite	al
Name hospital						
Date of hospital admission	From within this hospital	Date of admission	d			
		Emer	rgency departme	nt 📖		
I	From another hospital	ICU OR Non-I		me of hospital		
Clinical Details						
Was this respiratory infection		RSV) the primary	/ or contributing	cause for ICU a	dmission?	
Please select organisms that	t annly					
-		-				
SARS-CoV-2 (COVID-19)	Influenza A (not subtyped) Influenza B	-	(H1) pdm 2009 syncytial virus (R	sv)		
Co-infected with iGAS Yes	No Unknown					
Date of onset of symptoms		Date o	of diagnosis			
Was the infection determined t	to be hospital acquired?	Yes No	Unknow	m		
	SOFA scor	re on admiss	ion to this I	CU		
Parameter	0	1	2	3	4	Total
[PaO ₂ kPa /FiO ₂] ratio*	> 40	30-39	20-29	10-19	< 10	
Platelet count (10 ⁶ /L)	>150	≤150	≤ 100	<u>≤</u> 50	<u>≤</u> 20	
Bilirubin (umol/L)	< 20	20-32	33-100	101-203	> 203	
Hupstonsion	MAP	MAP	Dop≤5 or	Dop >5 or	Dop > 15 or	
Hypotension	> 70mmHg	< 70mmHg	equivalent	Epi ≤ 0.1 or Norepi ≤ 0.1	Epi > 0.1 or Norepi > 0.1	
605	15	13-14	10-12	6-9	< 6	
GCS	< 106	107-168	169-300	301-433	> 434	
GCS Serum Creatinine* (umol/L)						
Serum Creatinine* (umol/L) Total Does the patient have Acute R Does the patient require non-i	invasive advanced respiratory	y support (CPAP, B	iPAP or HFNO) or	Yes n admission? Yes Yes	No No No	*See Definitior – page 4
Serum Creatinine* (umol/L)	invasive advanced respiratory	y support (CPAP, B	iPAP or HFNO) or	n admission? Yes	No No	-

Underlying medical condition	Yes	No	Unknown
Does the case have any underlying medical conditions?			
Chronic heart disease			
Hypertension			
Chronic kidney disease			
Chronic liver disease			
Chronic neurological disease			
Cancer/malignancy including hematological ¹			
mmunodeficiency/Immunosuppression			
Due to HIV			
Due to Solid Organ Transplantation			
Due to Therapy (chemotherapy, radiotherapy, nigh dose steroids, immunomodulators, anti-TNF agents, etc. (see definitions pg 4)			-
Due to Primary immunodeficiency (see definitions pg4)			1
Due to inherited metabolic disorders			1
Due to Asplenia/ Splenic dysfunction			
Chronic respiratory disease including:			
Chronic obstructive pulmonary disease (COPD) (including horizon horizo			
Bronchiectasis			
Cystic fibrosis			
nterstitial lung fibrosis			
Asthma (requiring medication)			
Vild to moderate			
Severe (uncontrolled despite proper medication and			
Other			
Pregnant			
Neek of gestation			
s the case <= 6 weeks post partum			
Diabetes mellitus			
Гуре I			
Γγρe II			
Gestational diabetes			
Dbesity			
3MI <30			
3MI 30-40			
3MI >40			
Jnknown			
Hypothyroidism			
laemoglobinopathy			
Alcohol related disease			
her underlying medical conditions, please specify:			
ng status: Current smoker Never smoked Former smok	er (stopped smoki	ng≥1 year ago)	Unknown
es, leukaemia, lymphomas, blood dyscrasias or other malignant neoplasms e send Critical Care Admission Form to HPSC when patient is first a			J L

LC Influenza, RSV and	I COVID-19 Enhanced Surveillance Critical Care -	Adult
D ~	Part 2 – Discharge Form	npsc
Feidhmeannacht na Seirbhíse Sláinte Health Service Executive	C	

Patient Details	All information completed on the	is form should relate to the patient's cu	rrent ICU admission	
Forename	Surname		CIDR Event ID	
DOB	MRN			For HPSC use only
Name hospital			_	
Date of discharge from ICU		Length of stay in ICU (days)		
Clinical complication				
Please tick all that apply	Yes No		Yes No	
Primary viral pneumonia		Myocarditis Encephalitis		¹ See AKI Definition on
Secondary bacterial pneumonia				page 4
Acute Respiratory Distress Syndro	ome ²	Sepsis Acute kidney injury ¹		² See Berlin ARDs and AKI definitions on page 4 ³ See ICNARC definition on
Multiorgan failure ³		Respiratory Failure		page 4
Treatment interventio	'n			
Antivirals commenced Ye	s No Unknow	vn Date antiviral treati	ment commenced	
Please name antiviral used]		
Pressor dependence at any time during ICU stay	Yes No	Required Anticoagulation Treatment for a Thromb		No 🗌
CRRT/IHD	Yes No			
Non-invasive advanced respirat (CPAP, HFNO or BiPAP)	ory support Yes No			
CPAP/HFNO ventilation		Duration CPAP/HFNO ventila	tion (days)	
BiPAP ventilation		Duration BiPAP ventilation (lays)	
Invasive mechanical ventilation		Yes No		
Conventional (including lung pro	tective) mechanical ventilation	Duration co	nventional MV (days)
ЕСМО		Duration EC	MO (days)	
Discharge Informatio	n			
Transferred from ICU to: W *Other refers to a different hospi If transferred to other ICU, pleas If patient transferred to differen	tal se state name		er* ICU ECMC) abroad Died
Deaths				
If died, date of death:				
Is influenza a likely cause of deat	h? Yes	No 📃 Unknown 📃	Not applicable	e 🔄
Is COVID-19 a likely cause of dea	th? Yes	No Unknown	Not applicable	
Is RSV a likely cause of death?	Yes	No Unknown	Not applicable	e 🔄
Comments				
Signature		Date		
dult Influenza RSV & COVID 10 D	isobargo form Bart 2 (Bago 3 c	sf (1)		Version 4.2.09/08/2024

Influenza, RSV and COVID-19 Enhanced Surveillance Critical Care - Adult



Definitions

ARDS - Acute Respiratory Distress Syndrome

- Berlin Criteria
- Include all ARDS mild, moderate and severe

Timing Within 1 week of a known clinical insult or new/worsening respiratory symptoms

Chest Imaging*	Bilateral opacities not fully explained by effusion, lobar/lung collapse or nodules		
Origin of oedema	Needs objective assessment (e.g echocardiography) to exclude hydrostatic		
	no risk factor present		
Oxygenation	Mild	-26.6kPa < Pa0 ₂ /FiO ₂ = 39.9 kPa	
	Moderate	-13.3kPa < PaO ₂ / FiO ₂ = 26.6 kPa	
	Severe	$- PaO_2/FiO_2 = 13.3 kPa$	
	PEEP or CPAP = 5cmH2 all above		

*chest radiograph or CT ref.table modified from BJA Education, Vol 17 Number 5 2017

* FiO2 = inspired O2 concentration as a fraction of 1 (1=100% O2, 0.5 = 50% O2)

e.g if PaO2 =20 kPa and FiO2 = 0.5 then Paos/FiO2 ratio = 20/0.5 = 40.

Acute Kidney Injury

Use AKI classification

Stage	Creatinine Criteria		Urine output criteria
1	Cr. x 1.5–2 from baseline	or	<0.5 ml/kg/hr for 6 hours
2	Cr. x 2-3 from baseline	or	<0.5 ml/kg/hr for 12 hours
3	Cr. x 3 from baseline Or Cr?354 umol/I with an acute rise >44 umol/I or need RRT	or	< 0.3 ml/kg/hr for 24 hours or anuria for 12 hours or need for RRT

Multi organ failure

Using ICNARC definition

ICNARC define level 3 care as patients requiring organ support for two or more organ systems, excluding gastrointestinal support.

Immunodeficiency/Immunosuppression

Due to therapy	The following dose of prednisolone (or equivalent dose of other glucocorticoid) are likely to be immunosuppressive. Adults and children = 10kg: =40mg/day for more than 1 week or= 20mg/day for 2 weeks or longer; Children <10kg: 2mg/kg/day for 2 weeks or longer.
	Azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolic acid preparations, sirolimus and tacrolimus, in addition to biologics such as TNF α blocking agents (adalimumab, etanercept, infliximab), and others including abatacept, anakinra, eculizumab, rituximab and tocilizumab.
Due to primary	Ataxia Telangiectasia; Bruton agammaglobulinemia (X linked agammaglobulinemia,
immunodeficiency	XLA), Chronic granulomatous disease (CGD), Chronic mucocutaneous candidiasis
	(APECED syndrome), Complement deficiency, Common variable immunodeficiency
	(CVID) & other immunoglobulin deficiencies, DiGeorge syndrome, Down syndrome,
	Fanconi's anaemia, Wiskott Aldrich Syndrome, Severe combined immunodeficiency syndrome (SCID).

hpsc